Corbus Pharmaceuticals Holdings (CRBP) Depreciation & Amortization (CF) (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Depreciation & Amortization (CF) of $50000.0 for Q3 2025, down 67.11% year-over-year from $152000.0 in Q3 2024, and down 5.66% quarter-over-quarter from $53000.0 in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $50000.0 for Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) fell 67.11% year-over-year to $50000.0; the TTM figure through Dec 2025 stood at $184000.0 (down 68.71% YoY), while the FY2024 annual figure was $588000.0, down 8.27% from the prior year.
- Depreciation & Amortization (CF) for Q3 2025 stood at $50000.0, down from $53000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $272186.0 in Q1 2021, with the low at $50000.0 in Q3 2025.
- The 5-year median for Depreciation & Amortization (CF) is $158130.0 (2023), against an average of $167148.0.
- The sharpest annual moves came in 2021 and 2025: Depreciation & Amortization (CF) grew 26.82% in 2021, then plunged 67.11% in 2025.
- Corbus Pharmaceuticals Holdings' Depreciation & Amortization (CF) stood at $207685.0 in 2021, then dropped by 11.21% to $184397.0 in 2022, then declined by 19.74% to $148000.0 in 2023, then decreased by 9.46% to $134000.0 in 2024, then plunged by 62.69% to $50000.0 in 2025.
- Business Quant data shows CRBP's Depreciation & Amortization (CF) at $50000.0 in Q3 2025, $53000.0 in Q2 2025, and $81000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 153,000.00 |
| Sep 30, 2023 | 153,000.00 |
| Jun 30, 2023 | 158,130.00 |
| Jun 30, 2023 | 158,130.00 |